Skip to content

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
1.3×+0.1×
Incyte logo
IncyteINCY
3.7×+1.6×
Tango Therapeutics logo
Tango TherapeuticsTNGX
27.4×+21.1×
CG Oncology logo
CG OncologyCGON
31.3×+0.3×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
22.1×+2.2×

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×

Where this comes from

Calculated from Cogent Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s current ratio?
Cogent Biosciences, Inc. (COGT) reported current ratio of 15.1× in Q1 2026.
How has Cogent Biosciences, Inc.'s current ratio changed year-over-year?
Cogent Biosciences, Inc.'s current ratio increased by 195.3% year-over-year, from 5.1× to 15.1×.
What is the long-term trend for Cogent Biosciences, Inc.'s current ratio?
Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s current ratio has grown at a -5.3% compound annual growth rate (CAGR), from 18.7× to 14.2×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.